Literature DB >> 2424595

Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer.

P De Besi, V C Sileni, L Salvagno, C Tremolada, G Cartei, V Fosser, A Paccagnella, A Peracchia, M Fiorentino.   

Abstract

Forty patients with advanced squamous cell carcinoma of the esophagus were treated with a combination of cisplatin, 5-FU (by continuous 5-day infusion), and allopurinol; 37 are evaluable for response. Thirteen remissions (35%) were obtained, including three complete and ten partial, with a median duration of 9 months. After chemotherapy, seven responding patients underwent a surgical procedure, which was radical in four. The most frequent side effects were nausea and vomiting. This regimen is effective and can be included in a multimodality approach.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2424595

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  10 in total

1.  First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up.

Authors:  E Ancona; A Ruol; C Castoro; V Chiarion-Sileni; S Merigliano; S Santi; L Bonavina; A Peracchia
Journal:  Ann Surg       Date:  1997-12       Impact factor: 12.969

2.  Current gene expression studies in esophageal carcinoma.

Authors:  Wei Guo; Yao-Guang Jiang
Journal:  Curr Genomics       Date:  2009-12       Impact factor: 2.236

3.  Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Yuichi Sanada; Shinji Osada; Kazuya Yamaguchi; Takao Takahashi
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-28       Impact factor: 3.333

4.  5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research.

Authors:  X Pouliquen; H Levard; J M Hay; K McGee; A Fingerhut; O Langlois-Zantin
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

5.  Esophageal cancer chemotherapy: recent advances.

Authors:  David H Ilson
Journal:  Gastrointest Cancer Res       Date:  2008-03

6.  Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer.

Authors:  V Chiarion-Sileni; L Corti; A Ruol; R Innocente; C Boso; P Del Bianco; J Pigozzo; R Mazzarotto; O Tomassi; E Ancona
Journal:  Br J Cancer       Date:  2007-01-23       Impact factor: 7.640

7.  Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Atsuko Yamada; Toshiyuki Tanahashi; Naoki Okumura; Nobuhisa Matsuhashi; Kazuya Yamaguchi; Tatsuhiko Miyazaki
Journal:  Cancer Chemother Pharmacol       Date:  2016-02-20       Impact factor: 3.333

8.  Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.

Authors:  T C Kok; A Van der Gaast; J Dees; W M Eykenboom; H Van Overhagen; G Stoter; H W Tilanus; T A Splinter
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

9.  Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Toshiyuki Tanahashi; Naoki Okumura; Nobuhisa Matsuhashi; Kazuya Yamaguchi
Journal:  Cancer Sci       Date:  2016-05-12       Impact factor: 6.716

Review 10.  Recent advancements in esophageal cancer treatment in Japan.

Authors:  Yoshihiro Tanaka; Kazuhiro Yoshida; Tomonari Suetsugu; Takeharu Imai; Nobuhisa Matsuhashi; Kazuya Yamaguchi
Journal:  Ann Gastroenterol Surg       Date:  2018-05-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.